Kazia Therapeutics

(ASX:KZA)

We aspire to help patients and clinicians confront the most challenging cancers in modern medicine.

Kazia's drug candidates are designed to treated diseases such as brain cancer, renal cancer, and liver cancer, which are poorly served by existing therapies.

Email Alerts for:
ASX:KZA

Latest Media Releases

Kazia: AGILE hurdle missed but significant value remains

Corporate Connect analyst Marc Sinatra has today released an updated research report for ASX-listed biotech company Kazia Therapeutics (ASX: KZA), now available for download via the KZA company page…

Latest News

ASX rose 6.2% in January: Aus shares closed the day 0.07% lower

31 Jan 2023 - Australian shares fluctuated on Tuesday with a 0.4 per cent gain and later 0.2 per cent loss. Consumer stocks led the gains, up 2.3 per cent, while tech stocks weighe…

High cost of living causes a fall in retail sales: ASX up 0.22% at noon

31 Jan 2023 - Retail sales in Australia fell 3.9% in December, surprising expectations for a 0.2% decline. The ABS Head of Retail Statistics noted that the fall follows 11 consecut…

Almost all sectors higher: Aus shares close up 1%

01 Dec 2022 - Eight out of the eleven sectors have finished higher today, with big results from Materials, Utilities and Communication Services, whilst the sectors that were in the…

ASX opens to 7-month high after Powell's positive news: Aus shares up 0.8%

01 Dec 2022 - The ASX has reacted positively to overnight news from the Federal Reserve. Chair Jerome Powell has confirmed the central bank will slow the pace of interest rate rise…

US tech earnings weighing down Aus tech sector: ASX falls 0.62% at noon

28 Oct 2022 - Disappointing earnings from major US tech companies, including Meta, Apple and Amazon, has caused the Information Technology sector on the ASX to fall by 2.17 per cen…

Stocks of the Hour: Kazia Therapeutics, Green Technology Metals, Winsome Resources

28 Oct 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics(ASX:KZA), Green Technology Metals (ASX:GT1) and Winsome Resources (ASX:WR1).

Stocks of the Hour: Kazia Therapeutics, Mesoblast, BHP & Oz Minerals

08 Aug 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics (ASX:KZA), Mesoblast (ASX:MSB), BHP Group (ASX:BHP) and Oz Minerals (ASX:OZL).

ASX edges lower in morning trading, reporting season kicks off: Aus shares down 0.2% at noon

08 Aug 2022 - The labour market added 528,000 jobs in July, easily beating a Dow Jones estimate of a 258,000 increase. The unemployment rate ticked down to 3.5 per cent, below the …

Tech snaps 4-day winning streak, Iron ore miners rebound: ASX closes 0.8% higher

07 Jul 2022 - Despite the materials sector leading the gains, the sector offset losses in industrials, information technology, property, and communication services, the main coal m…

Australia trade surplus hits record high, Chalice Mining soars on discovery: ASX up 0.2% at noon

07 Jul 2022 - Australian stocks have rebounded, lifted by the material sector. Gains in consumer staples and discretionary stocks have offset losses in information technology, whil…

Stocks of the Hour: Elsight, Kazia Therapeutics, Chalice Mining

07 Jul 2022 - A snapshot of the stocks on the move, featuring Elsight (ASX:ELS), Kazia Therapeutics (ASX:KZA), and Chalice Mining (ASX:CHN).

Stocks of the Hour: Kazia Therapeutics, Westgold Resources & Lake Resources

14 Jun 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics (ASX:KZA), Westgold Resources (ASX:WGX) & Lake Resources (ASX:LKE).

Sector Watch: Healthcare - M&A fever on the cards?

11 May 2022 - A snapshot of stocks in the healthcare sector, including Antisense Therapeutics (ASX:ANP), Kazia Therapeutics (ASX:KZA), and Immutep (ASX:IMM).

Nasdaq jumps as Dow falls, Immutep, Antisense, Pushpay, AGL, Star on watch: ASX poised to open lower

11 May 2022 - Wall St closed mixed lifted by information tech and M&A news in the biotech sector as dip buyers emerge ahead of the next CPI print. Shanghai stocks bucked the trend …

Kazia Therapeutics (ASX:KZA) announces positive results for brain cancer drug

03 Dec 2021 - Kazia Therapeutics (ASX:KZA) has announced positive results from its Phase II study into the treatment of glioblastoma with paxalisib.

Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial

09 Dec 2020 - Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.

Kazia Therapeutics (ASX:KZA) glioblastoma Phase II trial results

27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE …

Kazia Therapeutics (ASX:KZA) clinical trial update presentation, FNN Investor Event, October 2018, Sydney

22 Oct 2018 - Kazia Therapeutics Limited (ASX:KZA) CEO and Executive Director Dr James Garner provides an update on the company's two clinical stage drug development candidates for…

Kazia Therapeutics (ASX:KZA) clinical trial update